Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB Redeye Interview Transcript

Oct 22, 2021 / NTS GMT
Release Date Price: kr105.3 (-3.48%)
Johan Unnerus
Redeye AB, Research Division - Senior Equity Analyst

My name is Johan Unnerus. I'm an analyst at the life science team at Redeye.

Today, we have the pleasure to feature Hansa Biopharma with the CEO, Søren Tulstrup. And we have some questions for Søren.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you. Good to be here.

Johan Unnerus
Redeye AB, Research Division - Senior Equity Analyst

Excellent, yes.

Questions & Answers

Johan Unnerus;SÃ;ren Tulstrup;publ
Redeye AB, Research Division - Senior Equity Analyst;Hansa Biopharma AB

You just reported your Q3, and overall, congratulations. You -- Idefirix is approved. And it's addressing a need for patients that hasn't had any products on the market that are highly sensitized ahead of kidney transplants. It's a big step forward, isn't it?

¸ - ()

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot